Marva I. Sweeney-Nixon

BSc, MSc, PhD
Professor, Chair
Phone: 
(902) 566-0633
Department: 
Biology
Office: 
Duffy Science Centre, 442
Education: 
BSc (Mt Allison)
MSc (Dalhousie)
PhD (Dalhousie)

Dr Sweeney moved to UPEI in August 1997, after a short stint as an Assistant Professor in the Dept. of Physiology, University of Saskatchewan, and Principal Investigator in the Saskatchewan Stroke Research Center, Royal University Hospital, Saskatoon.  Previously, she completed a Ph. D. in Pharmacology at Dalhousie University (Halifax, NS), and an MRC-funded  post-doctoral research fellowship at the University of London (St. George’s Hospital and Royal Free Hospital Schools of Medicine, UK).

Click here for Dr. Sweeney's Curriculum Vitae.

Dr Sweeney is a member of the Atlantic Canada Network on Bioactive Compounds (ACNBC; Team lead, Blueberry Research Project) and holds a 3 year Research Professorship in Nutrisciences and Health from the Louis Levesque Foundation (2005-2008). She studies health effects of bioactives from Vaccinium species (blueberries and cranberries) or other foods (e.g. pomegranate).

  • Effect of bioactive treatments of cells and feeding to animals on genes (nutrigenomics ); considers the relationship between specific nutrients/diets and gene expression and may facilitate prevention of diet-related diseases.
  • Effect of bioactive treatments of cells (e.g. with anthocyanins, flavonols and proanthocyanins) on oxidative stress, inflammation and relevant cancer genes (e.g. cell matrix metalloproteinases).
  • Effect of feeding bioactives to animals, using animal models of disease such as hypertension, stroke, and metabolic syndrome.
  • Effect of bioactives on human health; in order to produce natural health products, make health claims, or novel food products and additives, good research is needed.

All of this research is done by students and research associates, in collaboration with scientists at UPEI, other universities and government labs and is currently funded by NSERC, ACOA (Atlantic Innovation Fund/AIF), Heart & Stroke Foundation of PEI and the American Cranberry Institute. She is the author of 28 peer-reviewed publications, 7 book chapters or monographs, and 32 abstracts or conference proceedings. 

I.    Refereed manuscripts:

1.    Sawynok J., Sweeney M.I. and White T.D..  Classification of adenosine receptors mediating antinociception in the rat spinal cord.  Br. J. Pharmacol. 88: 923-930, 1986.

2.    Sweeney M.I. and Sawynok J..  Evidence that substance P may be a modulator rather than a transmitter of noxious mechanical stimulation.  Can. J. Physiol. Pharmacol. 64: 1324-1327, 1986.

3.    Sweeney M.I., White T.D., K.H. Jhamandas and Sawynok J..  Morphine releases endogenous adenosine from the spinal cord in vivo.  Eur. J. Pharmacol. 141: 169-170, 1987.

4.    Sweeney M.I., White T.D. and Sawynok J..  Involvement of adenosine in the spinal antinociceptive effects of morphine and noradrenaline.  J. Pharmacol. Exp. Ther. 243: 657-665, 1987.

5.    Sweeney M.I., White T. and Sawynok J..  5-Hydroxytryptamine releases adenosine from primary afferent nerve terminals in the spinal cord.  Brain Res. 462: 346-349, 1988.

6.    Sweeney M.I., White T.D. and Sawynok J..  Morphine, capsaicin and K+ release purines from capsaicin-sensitive nerve terminals in the spinal cord.  J. Pharmacol. Exp. Ther.248: 447-454, 1989.

7.    Sawynok J., Sweeney M.I. and White T.D..  Adenosine release may mediate spinal analgesia by morphine.  Trends in Pharmacol. Sci. 10: 186-189, 1989.

8.    Sawynok J. and Sweeney M.I..  The role of purines in nociception.  Neurosci. 32: 557-569, 1989.

9.    Sweeney M.I., White T.D. and Sawynok J..  5-Hydroxytryptamine releases adenosine and cyclic AMP from primary afferent nerve terminals in the spinal cord in vivo.  Brain Res.528: 55-61, 1990.

10.    Sawynok J., Sweeney M., Nicholson D. and White T.D..  Pertussis toxin inhibits morphine-induced adenosine release from the spinal cord.  Prog. Clin. Biol. Res. 328: 397-400, 1990.

11.    Sweeney M.I.,  White T.D. and Sawynok J..  Intracerebroventricular morphine releases adenosine and adenosine 3',5'-cyclic monophosphate from the spinal cord via a serotonergic mechanism.  J. Pharmacol. Exp. Ther. 259: 1013-1018, 1991.

12.    Scott R.H., Sweeney M.I., Kobrinsky E.M., Pearson H.A., Timms G.H. , Pullar I.A., Wedley S. and Dolphin A.C..  Actions of arginine polyamine on voltage and ligand-activated whole cell currents recorded from cultured neurones.  Br. J. Pharmacol. 106: 199-207, 1992.

13.    Sweeney M.I. and Dolphin  A.C..  1,4-Dihydropyridines modulate GTP hydrolysis by Go in neuronal membranes.  FEBS Lett. 310: 66-70, 1992.

14.    Huston E., Cullen G., Sweeney M.I., Pearson H., Fazel M.S. and Dolphin A.C.. Pertussis toxin treatment increases glutamate release and dihydropyridine binding sites in cultured rat cerebellar granule neurons.  Neurosci. 52: 787-798, 1993.

15.    Sweeney M.I., White T.D. and Sawynok J..  Morphine-evoked release of adenosine from the spinal cord occurs via a nucleoside carrier with differential sensitivity to dipyridamole and nitrobenzylthioinosine.  Brain Res. 614: 301-307, 1993.

16.    Sweeney M.I.and Dolphin  A.C..  Adenosine A1 agonists and the Ca2+ channel agonist Bay K 8644 produce a synergistic stimulation of the GTPase activity of Go in rat frontal cortical membranes.  J. Neurochem. 64: 2034-2042, 1995.

17.    Sweeney M.I., Yager J.Y., Walz W. and Juurlink B.H.J..  Cellular mechanisms involved in brain ischemia. Can. J. Physiol. Pharmacol. 73: 1525-1535, 1995.

18.    Sweeney M.I..  Adenosine release and uptake in cerebellar granule neurons both occur via an inhibitor-sensitive equilibrative nucleoside carrier which is modulated by G-proteins. J. Neurochem. 67: 81-88, 1996.

19.    Sweeney M.I. and Arneson  D.S..  Desensitization of adenosine receptors during brain hypoxia limits the neuroprotective effects of adenosine.  Can. J. Physiol. Pharmacol. 74: Axxxiv-xxxv, 1996.

20.    Logan M. and Sweeney M.I..  Adenosine A1 receptor activation preferentially protects neurons versus astrocytes against hypoxia-induced cell death. Mol. Chem. Neuropathol. 31: 119-133, 1997.

21.    Sweeney M.I..  Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Neurosci. Biobehav. Rev. 21: 207-217, 1997.

22.    Juurlink B.H.J. and Sweeney M.I..   Mechanisms that result in damage during and following cerebral ischemia. Neurosci. Biobehav. 21: 121-128, 1998.

23.    Sweeney M.I.  and Lyon, M.E.  Selective effect of malathion on blood coagulation versus locomotor activity.  J. Environ. Pathol. Toxicol. Oncol. 18: 203-211, 1999.

24.    Sweeney M.I., Kalt W., MacKinnon S.L., Ashby J. and Gottschall-Pass K.T.  Feeding of diets enriched in lowbush blueberries (Vaccinium angustifolium) for six weeks decreases stroke severity in rats. Nutritional Neuroscience  5: 427-431, 2002.

25.    Matchett, M.D., MacKinnon, S.L., Sweeney, M.I., Gottschall-Pass, K.T., and Hurta, R.A.R. Blueberry flavonoids inhibit matrix metalloproteinase activity in DU145 human prostate cancer cells.  Biochem Cell Biol.  83: 637-643, 2005.

26.    Matchett, M.D., MacKinnon, S.L., Sweeney, M.I., Gottschall-Pass, K.T., and Hurta, R.A.R.  Inhibition of matrix metalloproteinase activity in DU145 human prostate cancer cells by flavonoids from lowbush blueberry (Vaccinium angustifolium): possible roles for protein kinase C and mitogen-activated protein-kinase-mediated events.  J. Nutr. Biochem. 17: 117-125, 2006 [Epub Aug 17, 2005].

27.    Neto, C.C., Krueger, C.G., Lamoureaux, T.L., Kondo, M., Vaisberg, A.J., Hurta, R.A.R., Curtis, S., Matchett, M.D., Yeung, H., Sweeney, M.I., Reed, J.D.  MALDI-TOF MS characterization of proanthocyanidins from cranberry fruit (vaccinium macrocarpon) that inhibit tumor cell growth and matrix metalloproteinase expression in vitro.  J. Sci. Food Agric. 86: 18-25, 2006 [Epub Oct 17, 2005].

28.    Slemmer, J.E.., Shacka, J.J., Sweeney, M.I. and Weber, J.T. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging.  Curr. Med. Chem. 15 (4): 404 - 414, 2008. 

II.     Book chapters and expositions, refereed:

1.    Sawynok J., Nicholson D.J., Sweeney M.I. and White T.D..  Adenosine release by morphine and spinal antinociception: role of G proteins and cyclic AMP.  NIDA Res. Monogr.105: 40-46, 1991.

2.    Dolphin A.C., Huston E., Pearson H., Menon-Johansson A., Sweeney M.I., Adams M.E. and Scott R.H..  G protein modulation of calcium entry and transmitter release.  Annals N.Y. Acad. Sci. 635: 139-152, 1991.

3.    Dolphin A.C., Menon-Johansson A., Campbell V., Berrow  N.  and Sweeney M.I..  Modulation of voltage-dependent calcium channels by GABAB receptors and G-proteins in cultured rat dorsal root ganglion neurons: relevance to transmitter release and its modulation. In Cellular  mechanisms of sensory processing: The somatosensory system. (L. Urban, ed.), Springer-Verlag, Heidelberg. pp. 47-61, 1994.

4.    Sweeney M.I..  Measurement of the GTPase activity of signal-transducing G-proteins in neuronal membranes.  In Methods in Molecular Biology, Vol. 41: Signal Transduction Protocols (D.A.Kendall & S.J. Hill, eds.), Humana Press, New Jersey. pp. 51-61, 1995.

5.    Sweeney M.I.  Adenosine A1 receptors inhibit necrosis and apoptosis induced by oxygen and glucose deprivation in cultured neurons.  Annals of the NY Academy of Sciences Conference entitled “Oxidative/Energy metabolism in neurodegenerative disorders” 2000.

6.    Neto, C. C., Sweeney-Nixon, M. I., Lamoureaux, T. L., Soloman, F, Kondo, M., MacKinnon, S. L.  Cranberry phenolics: Effects on oxidative processes, neuron cell death and tumor cell growth.  In Phenolic Compounds in Foods and Natural Health Products, American Chemical Society Symposium Series 909 (Shahidi F. and Ho C.-T., eds), pp. 271-282, 2005.

7.    Sweeney M.I.  Pomegranate juice consumption reduces simulated ischemic stroke damage and increases brain antioxidant status in rats.  In “Pomegranate: Ancient Roots to Modern Medicine”, (N. Seeram, R. Schulman and D. Heber, eds.), CRC Press, pp. 91-106, 2006.

III.    Abstracts and conference presentations:

1.    Sweeney M., White T. and Sawynok J..  Characterization of adenosine receptors producing antinociception following intrathecal injection.  Proceedings of the Can. Fed. Biol. Sci. 29: 112, 1986.

2.    Sweeney M.I., White T.D. and Sawynok J..  Involvement of adenosine in the analgesic effect of morphine and noradrenaline in the spinal cord.  Soc. Neurosci. Abstracts 12: 1018, 1986.

3.    Sweeney M.I., White T.D. and Sawynok J..  Effect of intrathecal pretreatment with neurotoxins on adenosine release from rat spinal cord synaptosomes.  Soc. Neurosci. Abstracts 13: 1388, 1987.

4.    Sweeney M.I., White T.D. and Sawynok J..  Morphine releases adenosine from capsaicin-sensitive neurons in the spinal cord. Proceedings of the Can. Fed. Biol. Sci. 31: 80, 1988.

5.    Sweeney M.I., White T.D. and Sawynok J..  Serotonin releases adenosine from primary afferent nerve terminals in the spinal cord: possible involvement in spinal antinociception. Soc. Neurosci. Abstracts 14: 852, 1988.

6.    Sweeney M.I., White T.D. and Sawynok J..  Morphine-evoked release of adenosine from the spinal cord occurs via a dipyridamole-sensitive carrier.  J. Neurochem. (Suppl.) 52: S99B, 1989.

7.    Sweeney M.I., White T.D. and Sawynok J..  Adenosine, but not its phosphorylated nucleotides, is released from the spinal cord via a dipyridamole-sensitive carrier.  InAdenosine Receptors in the Nervous System, ed. J.A. Ribeiro, Taylor and Francis (London): 213, 1989.

8.    Sweeney M.I., White T.D. and Sawynok J..  Adenosine release from the spinal cord may mediate antinociception by intracerebroventricular morphine.  Soc. Neurosci. Abstracts15: 371, 1989.

9.    Sweeney M.I., White T.D. and Sawynok J..  Intracerebroventricular morphine releases cyclic AMP and adenosine from the spinal cord via a serotonergic mechanism.  Eur. J. Pharmacol. 183: 1450-1451, 1990.

10.    Sweeney M.I., and Dolphin A.C..  Biochemical evidence that dihydropyridine and GABAB receptors interact with Go and Gi respectively. Soc. Neurosci. Abstracts 17: 68, 1991.

11.    Sweeney M.I. and Dolphin A.C..  Biochemical evidence that GTP binding proteins are directly coupled to dihydropyridine receptors.  Proceedings of the Eur. Neurosci. Assoc., abstract # 1047, 1991.

12.    Sweeney M.I. and Dolphin A.C..  The GABAB receptor agonist (-)-baclofen and the 1,4-dihydropyridine Ca2+ channel agonist Bay K 8644 modulate the GTP-binding protein Go via different mechanisms.  Br. J. Pharmacol. (Suppl.) 107: 240P, 1992.

13.    Sweeney M.I. and Dolphin A.C..  Adenosine A1 agonists stimulate the GTPase activity of Gi- and Go-type G-proteins in cortical membranes: synergism with Bay K 8644.  J. Neurochem. (Suppl.) 61: S78D, 1993.

14.    Sweeney M.I..  Activation of adenosine receptors protects neurons from ischemia-induced death.  Soc. Neurosci. Abstracts 20: 1042, 1994.

15.    Sweeney M.I. and M. Logan.  Endogenous adenosine protects neurons but not astrocytes from hypoxic cell death. Proceedings of the Can. Fed. Biol. Soc. 38: 58, 1995.

16.    Sweeney M.I., Arneson D.S. and Murton A.  Adenosine A1 receptor agonists prevent delayed neuronal death following ischemia. Soc. Neurosci. Abstracts 22: 1433, 1996.

17.    Sweeney M.I. and Arneson D.S.  The adenosine agonist CPA inhibits necrosis but promotes apoptosis induced by simulated ischemia in neuronal cultures. Soc. Neurosci. Abstracts 23: 1924, 1997.

18.    Sweeney M.I.  and Campbell, D.S. Adenosine A1 receptors precondition the rat brain against hypoxia-ischemia damage one day later.  Soc. Neurosci. Abstracts 25: 2051, 1999.

19.    Rigley S.T., Sweeney M.I. and R.A.R. Tasker.  Cyclopentyladenosine decreases apoptotic cell death in cerebellar granule neurons after oxygen-glucose deprivation.  Soc. Neurosci. Abstracts 26: 2067, 2000.

20.    Campbell D.S. and Sweeney M.I. . Adenosine agonist reduces hypoxia-ischemia induced cell death in the hippocampus of male rats.  Soc. Neurosci. Abstracts 26: 508, 2000.

21.    Sweeney-Nixon, M., Blacquiere, D., Ashby, J., MacKinnon, S., Kalt, W. & Gottschall-Pass, K.. Short term diets enriched with wild blueberries decrease stroke severity in rats.Proc of the Can. Fed. Biol. Soc. 44: 56,  2001.

22.    Gottschall-Pass, K., Rogers, L., Ashby, J., MacKinnon, S., Kalt, W., Sweeney-Nixon, M.. Wild blueberry extracts produce modest improvements in predictors of cardiovascular disease in cholesterol fed rabbits. Proceedings of the Can. Fed. Biol. Soc. 44: 57, 2001.

23.    Sweeney M.I., K.J. Clark, S. MacKinnon, W. Kalt and K.T. Gottschall-Pass.  The effects of individual fractions of lowbush (wild) blueberries (Vaccinium angustifolium) on primary cultured neurons after simulated ischemic stroke and oxidative stress.   PEI Health Research Institute Forum (May 2002).

24.    Sweeney M.I.,  Rigley S.T., Campbell D.S. and Tasker R.A.R.  A1-adenosine receptor activation several hours before stroke decreases necrotic and apoptotic death in vitro and in vivo.  Soc. Neurosci. Abstracts 28:  2002.

25.    Dunsford, C., Sweeney M.I., and Gottschall-Pass, K.T.  Lowbush blueberry consumption reduces atherosclerotic plaque size in hypercholesterolemic rabbits. Proceedings of the Can. Fed. Biol. Soc. 46: 64,  2003.

26.    Sweeney M.I., Soloman F. and Neto, C.C.  Antioxidant rich fractions isolated from cranberries reduce neuronal death in response to simulated ischemic stroke and reperfusion injury in vitro.  Proceedings of the Can. Fed. Biol. Soc. 46: 92,  2003.

27.    Sweeney M.I., Gottschall-Pass, K.T., Clark , K.J. and Durant, C. Anthocyanins Isolated from Lowbush Blueberries (Vaccinium Angustifolium) Inhibit Oxidative Stress-induced Nitrite Accumulation and NOS Induction in Cultured Cerebellar Granule Neurons.  (Presented at Experimental Biology ‘04, Washington, DC) 2004.

28.    Gottschall-Pass, K., Macdonald, K., Garrity, E., Pass, E., LeClair-Morrison, S. &Sweeney, MI. Extracts from wild blueberries (Vaccinium angustifolium) reduce markers of LPS-induced inflammation in the rat. (Presented at Experimental Biology ‘05, San Diego, CA), 2005.

29.    Sweeney M.I., Harmon, M.I., Durant, C.D., Soloman, F. and Schulman, R.N.  Pomegranate juice consumption reduces simulated ischemic stroke damage and increases brain antioxidant status in rats.  (Presented at Experimental Biology ‘05, San Diego, CA), 2005.

30.    M. Sweeney, K. Shaughnessy, K. Gottschall-Pass.  Blueberry diets delay the onset of hypertension and reduce insulin resistance in spontaneously hypertensive stroke prone rats.  FASEB J. 21(6): A1092, 2007.

31.    K. Shaughnessy, M. Sweeney, and C. Neto . Investigation of the effects of cranberry fractions on atherosclerosis in mice.  FASEB J. 21(6): A1093, 2007.

32.    K. Gottschall-Pass, M. Wark, H. Yeung, E. Pass, S. Purcell, R. MacPhee & M.I. Sweeney.  Blueberry supplementation lowers iNOS but not COX-2 expression in LPS challenged rats.  FASEB J. 21(6): A36, 2007.

Invited Presentations & Public Awareness

October 1990, American Pain Society Annual Meeting, St. Louis, MO.  Title: “Preparations used to study adenosine release from the spinal cord”.

April 1994, Dept. of Veterinary Physiological Sciences, Western College of Veterinary Medicine, University of Saskatchewan.  Title: “Adenosine as a neuromodulator in the central nervous system: therapeutic implications in analgesia and stroke”. 

September 1994, Dept. of Anatomy, University of Saskatchewan.  Title:  “Protective effect of adenosine against cell damage in an in vitro stroke model”.

June 1995, Saskatchewan Stroke Research Center Symposium “Cellular mechanisms involved in cerebral ischemia”, Saskatoon.  Title:  “Endogenous adenosine: the good, the bad, and the ugly”.

October 1995, Dept. of Pharmacology, Dalhousie University, Halifax.  Title:  “Endogenous adenosine in cerebral ischemia: the good, the bad, and the ugly”.

April 1996, Dept. of Pharmacology, University of Saskatchewan, Saskatoon.  Title:  “Neuroprotective effects of adenosine in cerebral ischemia: therapeutic window of opportunity”.

August 1996, Dept. of Anatomy, University of Saskatchewan, Saskatoon.  Title:  “Adenosine: endogenous protector of ischemia-induced delayed neuronal death”.

June 1997, Dept. of Biology, UPEI.  Seminar title: “Neurobiological roles for adenosine: friend or foe?” Lecture title: “The Physiology of Hibernation”.

July 1998, Dept. of Anatomy & Physiology, Atlantic Veterinary College, UPEI.  Title: “Adenosine in the CNS: therapeutic implications in analgesia and stroke”.

November 1998, Faculty of Science seminar series, UPEI.  Title: “The wonders of adenosine in the brain: relevance to strokes, coffee drinkers and diving turtles.”

April 1999, University of Prince Edward Island Research Breakfast.  Title: “The importance of stroke research: is chronic caffeine drinking a good preventative strategy ?”.

June 1999, Rotary Club of Charlottetown, Invited Speaker. Title “Stroke prevention”.

November 1999, Dept. of Biology, St. Francis Xavier University, Antigonish NS.  Title: “The wonders of adenosine in the brain: relevance to strokes, coffee drinkers and diving turtles.”

February 2000, Heart & Stroke Foundation of PEI, Launch of Heart Month, Tim Hortons Restaurant, Summerside PEI. Title: “Preserving our nerve cells in stroke”.

March 2001, Dept. of Biology, University of New Brunswick, Fredericton NB.  Title: “Protecting neurons from hypoxia: are blueberries the answer ?”.

August 2001, Dept. of Pharmacology, University of Saskatchewan, Saskatoon SK.  Title: “Preventing cardiovascular disease: are dietary blueberries the answer ?”.

May 2002, PEI Health Research Institute Forum, Brudenell PEI.  Title: “Effects of individual fractions of lowbush blueberries on cultured neurons after simulated stroke and oxidative stress”.

December 2002, CBC’s Quirks and Quarks radio show.  Title: Is there colour vision in mammals ?

May 2003, PEI Health Research Institute Forum, Crowbush Resort, PEI. Title:  Antioxidant rich fractions from cranberries reduce neuronal death in response to simulated stroke and reperfusion in vitro.”.

October 2003, Dept. of Biology, Mt Allison University, Sackville NB.  Title: “Effects of Vaccinium phytochemicals on cardiovascular health.”

June 2004, Pom Wonderful Health Summit, Los Angeles, CA.  Title: “Evaluation of the neuroprotective effects of pomegranate juice on simulated ischemic stroke in rats.”

September 2004,  Nova Scotia Biotechnology and Life Sciences Industry Association (BioPort Nova 2004), Halifax, NS.  Title: “Building the Bio-Economy in Atlantic Canada”.

December 2004, PEI-WISE (Women in Science & Engineering), UPEI.  Title: “Studying the Health Benefits of Berries: Lessons in WiSE.  What/Why/How to Survive and Stay Encouraged & Excited”.

October 2005, Canadian Herb, Spice & Natural Health Products Coalition, National Conference 2005, St. John’s, Newfoundland.  Title: “Connecting Agriculture to Health”.  Talk entitled “Blueberries - more than just antioxidants”.

November 2005, New Brunswick Horticulture Congress 2005, Moncton, NB. Title: “The power of blue: the science of health effects of wild blueberries”.

February 2007, PEI Health Research Institute “Lunch & learn” series.  Title: “Getting Healthy With Berries”.

November 2007, Dept. Of Chemistry & Biochemistry, University of Massachusetts (at Dartmouth).  Title: “Berries: Interdisciplinary Approaches to Evaluating Healthy Foods .”

March 2008, Atlantic Cranberry Management Course, Charlottetown PEI.  Title: “Cranberries – an update on health effects”.

April 2008, Sanofi-Aventis BioTalent Challenge, Biotech Luncheon, Charlottetown PEI.  Title: “Biosciences @ UPEI”.

Undergraduate courses

  • Biology 102, Human Biology
  • Biology 121/122, Human Anatomy & Physiology
  • Biology 221, Cell Biology
  • Biology 232, Pharmacology for Nurses
  • Biology 326, General Physiology
  • Biology 401, Human Physiology & Pathophysiology
  • Biology 402, Animal Physiology
  • Biology 490, Honors Research & Thesis

Graduate courses

  • Biology 811, Advanced Topics in Cell and Molecular Biology
  • Veterinary Biomedical Sciences 852, Introduction to Neuroscience

Recent Administrative responsibilities

  • 2003-2005, UPEI Sexual Harassment Committee;
  • 2005-present, Fair Treatment Committee
  • 2004-2006, University Marshal and Member of Convocation Committee;
  • 2006-2009, Chair, Convocation Committee.
  • 2006-2010, University Review Committee
  • 2007-present, ACCBR Management Committee
Contact UPEI